Vivos Therapeutics entered a letter agreement with Streeterville Capital to extend the deadline for a required $2.6 million qualifying financing. The original deadline of June 15, 2026, was extended to August 31, 2026. The agreement facilitates the conversion of up to $4.5 million of outstanding debt into perpetual, non-convertible preferred stock and common stock. The extension is intended to provide the company more time to conduct an organized equity raise and a planned rights offering.